Drug Target Review

APRIL 7, 2025

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Target Review

NOVEMBER 25, 2024

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Drug Target Review

JULY 23, 2024

This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

Drug Target Review

APRIL 7, 2025

In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent). To qualify as endpoints, biomarkers used in early phases must be relevant to later stages of drug development.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

LifeSciVC

JANUARY 16, 2024

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Small molecule GLP1s?

Small Molecule 143

Small Molecule Trials Therapies Disease 143

ASPET

SEPTEMBER 7, 2023

Avalglucosidase alfa has received marketing authorization in several countries for infantile-onset and/or late-onset Pompe disease. This recently approved enzyme replacement therapy (ERT) was glycoengineered to maximize CIMPR binding through high-affinity interactions with ~7 bis-M6P moieties.

Small Molecule 100

Small Molecule Therapies Disease Treatment 100

Practical Cheminformatics

JANUARY 8, 2024

Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Most of the LLM activity in the drug discovery space in 2023 was reported as preprints from academic groups. Most of the drug discovery examples were underwhelming. Here’s the structure of Part II.

Drugs 136

Drugs Small Molecule Bioinformatics Packaging 136

Alta Sciences

NOVEMBER 5, 2024

Since poorly soluble drugs are difficult to formulate as tablets, formulation scientists are looking to two-piece, liquid-filled hard-shell capsules as a solution. And when it’s time to go to market, the scale-up of the manufacturing process for commercialization is straightforward. Why Liquid-Filled, Hard-Shell Capsules?

Marketing 52

Marketing Small Molecule Production Pharmaceuticals 52

The Premier Consulting Blog

NOVEMBER 20, 2024

In the case of urgent or immediate public interest, process validation may be conducted concurrently with manufacturing the commercial small molecule or biologic product to expedite product availability for patients. It ensures that a production process consistently yields products of predetermined quality and safety.

Small Molecule 52

Small Molecule Drugs FDA Production 52

The Pharma Data

JUNE 9, 2025

Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational small molecule developed by Abbisko Therapeutics Co., In parallel, we are working to file a New Drug Application (NDA) to the U.S. Food and Drug Administration, with additional filings planned in other markets.”

Treatment 40

Treatment Therapies Small Molecule Marketing 40

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov. The program was initiated in April 2020.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) International Molecular Biology 40

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. Chief Executive Officer of Biohaven, said: “We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery. TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Nvidia Developer: Drug Discovery

MARCH 21, 2023

Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Generate small molecules with specific properties.

Small Molecule 52

Small Molecule Drugs Clinical Trials DNA 52

The Pharma Data

JANUARY 25, 2021

.–( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Strovel, PhD, Chief Executive Officer of Veralox Therapeutics. About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

Molecular Design

DECEMBER 31, 2024

My pulse will be quickenin' With each drop of strychnine We feed to a pigeon It just takes a smidgin To poison a pigeon in the park Tom Lehrer, Poisoning Pigeons in the Park | video ** Ill be reviewing the H2024 study (Occurrence of Natural Selection in Successful Small Molecule Drug Discovery) in this post.

Small Molecule 85

Small Molecule Drugs Production Science 85

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. Cavlan notes that underpinning this use of AI in early discovery is the need to better understand biology.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

LifeSciVC

APRIL 24, 2024

Is a novel target at the inflection point where enough evidence is available to suggest it may prove to be a compelling drug? and whether a molecule’s pharmacology can help to mitigate safety risk. In order to start building a case for or against a target, I like to start with genetics – first human and then mouse. in liver, in CNS)?

Production 131

Production Small Molecule Regulations Trials 131

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Pharmaceutical Companies 52

LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more. a company with the strongest pipeline in the entire industry.”

Molecular Biology 100

Molecular Biology Production Drug Development Small Molecule 100

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. Stability Tests: For small molecule, only -20°C stability testing is required, while large molecule need both -20°C and -70°C tests if samples are intended for storage at these temperatures.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

The Pharma Data

OCTOBER 4, 2021

In a recent paper, researchers at GlaxoSmithKline (GSK) and the Cambridge Crystallographic Data Centre (CCDC) combined their proprietary (GSK) and published (CCDC) datasets to better train machine learning (ML) models to predict stable polymorphs to use in new drug candidates. What are the key differences between the CCDC and GSK datasets?

Small Molecule 52

Small Molecule Drugs Pharmaceuticals Research 52

Alta Sciences

FEBRUARY 10, 2025

As a leading CRO, we provide a suite of unparalleled services designed to streamline your path to market. Contact us to get started!

Small Molecule 52

Small Molecule Clinical Trials Drug Development Trials 52

The Pharma Data

NOVEMBER 22, 2020

SAN DIEGO–( BUSINESS WIRE )– Vividion Therapeutics , a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer. market access.

Small Molecule 52

Small Molecule Pharmacy Pharmaceuticals Science 52

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta ®. –(BUSINESS WIRE)– Kite Pharma, Inc.,

Therapies 40

Therapies Marketing Small Molecule Science 40

Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD in 2023 to $166.53 billion USD by 2028.

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52

The Premier Consulting Blog

SEPTEMBER 11, 2024

The 505(b)(2) new drug application (NDA) pathway offers a unique opportunity for small molecule developers to bring innovative products to market more efficiently by leveraging existing data they do not own or have right of reference to. The new formulation resulted in a drug product that was very viscous.

Drugs 52

Drugs Clinical Pharmacology Packaging Small Molecule 52

PerkinElmer

SEPTEMBER 8, 2019

Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe. Learn more about Cisbio here.

Cell Based Assays 52

Cell Based Assays Small Molecule Science Pharmaceuticals 52

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

Drug Target Review

JUNE 19, 2024

Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. Just like small molecules and antibodies, cell therapies are changing how we treat patients. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JANUARY 5, 2024

fowleri cases 3 suggest that combinations of antibiotic and antifungal drugs, including azithromycin, amphotericin B, fluconazole, rifampin and miltefosine (the latter originally formulated for leishmaniasis and cancer chemotherapy 4 ), have a minimal impact on survival. Recent reviews of N.

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. ” Prof.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

The Pharma Data

JANUARY 13, 2021

PITTSBURGH–( BUSINESS WIRE )– Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma. Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

Sygnature Discovery

OCTOBER 10, 2023

On 10th October 2023, Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) experts, Axol Bioscience.

Small Molecule 52

Small Molecule Drugs Disease Clinical Trials 52

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

DECEMBER 15, 2020

The seed round will enable Enveda to grow its medicinal plant dataset, enhance its technologies and algorithms to further accelerate natural product drug discovery and advance its lead asset for liver fibrosis through preclinical development. They have also inspired more than 20 percent of the new drugs that have been approved since 1981.

Small Molecule 52

Small Molecule Production Laboratories Engineering 52